ABSTRACT The effects of two antianginal drugs, nicorandil and isosorbide dinitrate (ISDN), on metabolism and function of the ischemic myocardium were studied in a preparation of Nicorandil, but not ISDN, improved %SS during reperfusion. Endocardial ATP and total adenine nucleotides were preserved in both nicorandil-and ISDN-treated hearts. Tissue edema was also attenuated by both compounds. Thus, nicorandil improved both function and metabolism during recurrent myocardial ischemia independent of a hemodynamic effect, whereas ISDN only attenuated the loss of adenine nucleotides and increase in tissue water.
REPETITIVE, brief episodes of myocardial ischemia are common during angina pectoris in patients with coronary artery disease. Intermittent cross-clamping or repeated, brief periods of coronary artery occlusion are also used during cardiac surgery. However, it is not clear from experimental studies whether recurrent ischemic episodes of brief duration have a cumulative effect on the development of regional postischemic myocardial dysfunction. [1] [2] [3] [4] Nicorandil [SG-75; 2-nicotinamidoethyl-nitrate (es- ter)] has been developed as a new antianginal drug with potent vasodilating properties. It has recently been shown to improve postischemic segment dysfunction in anesthetized5 and conscious6 dogs after a single 10 or 15 min coronary artery occlusion. The improvement in postischemic myocardial function after nicorandil may be partially related to a reduction in afterload, but the improved functional recovery in the presence of nicorandil is significantly greater than that after an equihypotensive dose of nifedipine. Thus suggests that the beneficial effects of nicorandil on the ischemic myocardium may be independent of peripheral hemodynamics and that other mechanisms must be involved in its action. The purpose of this study was to determine whether there is a metabolic component of the action of nicorandil independent of its hemodynamic effect that CIRCULATION might explain its salient effect on postischemic myocardial function. Thus, we purposely chose a low dose of nicorandil that would not significantly alter the ratepressure product or myocardial oxygen consumption to determine whether the recovery of contractile function was enhanced after reperfusion. The experimental preparation of repeated, short periods of coronary artery occlusion was chosen for these studies to mimic the recurrent ischemia of anginal attacks observed clinically. Isosorbide dinitrate was chosen for purposes of comparison because this compound has a similar hemodynamic profile and plasma half-life to those of nicorandil.
Methods
Surgical preparation and functional analysis. Twenty-four adult mongrel dogs (15 to 25 kg) of both sexes were used in this study. Animals were anesthetized with an intravenous combination of 15 mg/kg sodium pentobarbital and 200 mg/kg barbital sodium. Dogs were ventilated with a Harvard respirator (tidal volume of 15 ml/kg and 10 to 15 respirations per min) and supplemented with 100% oxygen. Atelectasis was prevented by maintaining a trap with an end-expiratory pressure of 5 to 7 cm of water. Body temperature was maintained at 380 C with a heating pad. Blood gases were monitored (ABL-2) at various times throughout the experiment and kept within the normal physiologic range.
Mean arterial and left ventricular pressures were monitored by inserting a double pressure transducer-tipped catheter (Millar PC 771) into the aorta and left ventricle via the left carotid artery. Left ventricular dP/dt was determined by electronic differentiation of the left ventricular pressure pulse. The right femoral vein was cannulated for the administration of drugs.
A left thoracotomy was performed at the fifth intercostal space, the pericardium was incised, and the heart was suspended in a cradle. A portion of the left anterior descending coronary artery (LAD) was isolated and an electromagnetic flow probe (Statham SP 7515) was placed around the vessel. LAD coronary blood flow was measured with a flowmeter (Statham 2202). Distal to the flow probe, a micrometer-driven mechanical occluder was placed to produce a total occlusion of the LAD. The electrocardiogram was monitored using limb lead II and a tachograph was used for a continuous measurement of heart rate. All measurements were monitored on a Grass Model 7 polygraph. A cannula was positioned via the left external jugular vein in the local anterior intraventricular coronary vein, which drained the ischemic LAD area to obtain blood samples (figure 1). The cannula tip always lay just distal to the coronary occluder to ensure sampling primarily from the ischemic-reperfused area. Roberts et al. 8 Tween 80 added to prevent aggregation. The radioactive microspheres were ultrasonicated for 5 min followed by 5 min of vortexing. Approximately 2 to 4 x 106 spheres were injected into the left atrium followed by a 6 ml saline wash. Just before sphere administration, a reference blood flow sample was withdrawn from the femoral artery at a constant rate of 6.5 mllmin for 3 min.
At the completion of each experiment, India Ink was injected into the LAD to delineate the perfusion area. The heart was removed and stored overnight in 10% formalin. The heart was sectioned into subepicardium, midmyocardium, and subendocardium of the normal (three pieces) and ischemic regions (five pieces) and the tissue samples were weighed. All samples were counted (Searle Analytic 1 195) to determine the activity of each isotope in each sample. The activity of each isotope was also determined in the reference blood flow samples. Myocardial Blood chemical analysis. Arterial and local coronary venous blood samples were collected into ice-chilled tubes containing sodium fluoride (to prevent glucose metabolism in vitro) and potassium oxalate (anticoagulant). A 0.5 ml aliquot of the collected blood was immediately added to 1.0 ml of ice-cold, 6%5 perchloric acid for deproteination. Samples were then 2entri-fuged and enzymatically analyzed within 3 hr for blood lactate (Sigma Diagnostics) with the use of a Gilford 250 recording spectrophotometer.
The remaining blood was centrifuged to obtain plasma for both glucose and free fatty acid (FFA) period in control or nicorandil-treated hearts (data not shown). However, in the ISDN group, transmural myocardial blood flow in the nonischemic area decreased from a baseline of 0.93 ± 0.08 ml/min/g in the first occlusion period to 0.68 + 0.06 and 0.73 ± 0.08 ml/min/g in the second and third occlusion periods. The endo/epi blood flow ratio was 1.28 ± 0.4 and 1.11 ± 0.08, respectively. In the ischemic region, blood flow decreased markedly and to a similar extent during all three occlusion periods in the three groups (figure 3). In addition, the left ventricular weights, ischemic area weights, and the percent area at risk for ischemia were similar in all groups (left ventricular weights: 100. ening. There were no significant differences between groups during the occlusion periods ( figure 4) .
During the first 30 min reperfusion period in the absence of drugs, the recovery of %SS in the three groups was similar (figure 4). Immediately after drug treatment during the second 30 min reperfusion period, %SS in nicorandil-treated dogs recovered 100% as compared with the initial control 1 value, whereas %SS in the saline and ISDN-treated dogs was significantly decreased (p < .05) compared with their respective control 1 values (figure 4). When the %SS values during the second 30 min reperfusion period were compared with their respective control 2 values, %SS in nicorandil-treated dogs recovered to a greater extent than those in the saline and ISDN-treated animals and %SS in the ISDN group was significantly increased with that in the control group (figure 5). At the end of the third 30 min reperfusion period, functional recovery in all three groups was depressed and %SS was approximately 30% to 40% less than the original control 1. While the uptake of FFA was reduced during each period of ischemia in all three groups compared with the uptake in the respective control period, that in untreated hearts during both the second control and second ischemic period was increased relative to that during the first control and ischemic period. During ischemic periods in untreated hearts, the uptake of FFA was twice as high in the second as in the first ischemic period (figure 6). Nicorandil. but not ISDN. reversed this increase. When the net change in FFA uptake was calculated, there was an increase in FFA uptake in both the ischemic periods (2 and 3) that followed in untreated animals. This was not observed in the ISDN-treated group. In contrast, a net decrease in FFA uptake was observed in both ischemic penrods 2 and 3 in the nicorandil-treated group (figure 6).
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Myocardial lactate extraction. Uptake of lactate was reduced in all experimental groups during all three ischemic periods (table 5). There was no major alterations in the arterial and coronary venous concentra-CIRCULATION An increase in tissue water was also evident in the reperfused region of untreated hearts (figure 8). Both nicorandil and ISDN attenuated the tissue edema in the reperfused region after repetitive ischemic-reperfusion episodes.
Discussion
The observations in this study suggest that nicorandil may be an effective therapeutic agent in the treatment of recurrent myocardial ischemia. The salient effect of Each point represents the mean ± SEM of seven or eight hearts expressed in units of ,umoles per g dry weight.
ASignificantly different from corresponding layer in nonischemic zone. ,,oxygen wasting" phenomenon,22 it is possible that this could also explain why nicorandil prevented the decline in adenine nucleotides after multiple ischemic episodes. However, this does not appear to explain why ISDN preserved adenine nucleotides. It is possible that the preservation of adenine nucleotides by these two agents may be either unrelated to changes in substrate uptake during ischemia or arise from different mechanisms than those for improved functional recovery.
Relationiship to previous studies. In an isolated report on a preparation of recurrent ischemia, Korb et al.29 reported that nicorandil might have a detrimental effect during myocardial ischemia. They showed that nicorandil increased FFA metabolism and oxygen debt during a 3 min occlusion interval. The present study does not confirm these findings. Instead, our study suggests the opposite conclusion. There are some probable reasons for these discrepancies.
Korb et al.29 used coronary sinus blood for venous substrate and blood gas concentrations as well as for blood flow determinations. In contrast, we collected blood for venous substrates and blood gases from the local vein draining the ischemic bed. The local vein samples should be more representative of the ischemic area and not greatly contaminated from adjacent nonischemic sources, which may dilute blood samples obtained from the coronary sinus. Furthermore, we made our blood flow measurements in the ischemic area by the radioactive microsphere method. Again, this would be a more precise measure of ischemic myocardial blood flow than that obtained from measurements of coronary sinus blood flow. The flow value obtained for the determination of coronary sinus blood flow may have been artificially high due to the contribution of blood flow from adjacent nonischemic areas, which may contribute significantly to total coronary sinus blood flow. Thus, any calculations of substrate uptake based on measures of coronary sinus blood flow compound the error in measurement of coronary sinus substrate concentration and lead to erroneous conclusions.30, 31 Finally, in their preparation of repetitive occlusion Korb et al.29 used ischemia of different durations (3 min vs 5 min). It is not known whether this time differential is of significance. However, it is likely that Korb et al. could not differentiate a priming effect of repetitive ischemia because they combined their data from two to three control occlusions or two to three drug-treated occlusions within the same dog. The averaging of substrate utilization from multiple periods of occlusion or reperfusion within the same animal may not be justified based on our results.
Limitations and uniqueness of the preparation. The preparation of recurrent ischemia chosen for these studies was created by ischemic episodes of short duration. While most experimental protocols consist of ischemic durations of 10 min or longer, shorter periods may be relevant to certain clinical situations. The brevity of this ischemic interval may produce events that are not entirely characteristic of prolonged ischemia. It is likely that metabolic events arising during early myocardial ischemia (less than 5 min) are not similar to those occurring during ischemia of longer duration (more than 5 min). Thus, there is a progression of metabolic events that evolve from the transition from the nonischemic to the overtly ischemic myocardiumi2
It should be emphasized that our preparation is more representative of the initial transition phase of acute myocardial ischemia. One manifestation of this phase is that net lactate production by the heart has not yet commenced, although coronary venous blood lactate concentration may be increased. Since we collected local coronary venous blood samples for substrates between the third and fourth minute of ischemia, it is not surprising that not all hearts showed net lactate production during the ischemic interval. This observation is consistent with other investigators who observed only marginal lactate production after 5 min9 or significant lactate production after 10 min of ischemia.3' Alternatively, others have shown net lactate production only on reperfusion after a 2 min occlusion period.33 Unfortunately, we did not measure substrate utilization during early reperfusion. Such determinations would be complicated by the variability of the hyperemic blood flow and may not be an accurate index of lactate production.
Instead of focusing on the reperfusion phase for substrate utilization, we chose as one of our primary foci a comparison of events occurring during each ischemic interval since this might influence the functional recovery of the succeeding reperfusion period. Between the first and second occlusion cycles, we observed a priming effect on substrate utilization before and during the ischemic period. We know of no other study that has detected such a priming phenomenon. This is most likely because investigators who use a preparation of recurrent ischemia measure functional indexes rather than metabolic variables. Thus, our studies are unique in that regional myocardial blood flow, regional contractile function, regional MVO2, transmyocardial substrate uptake, and regional myocardial energy metabolism were all measured within the same hearts. It is not yet known whether the substrate priming after the first occlusion cycle is a compensatory mechanism to regenerate chemical energy stores and to CIRCULATION 926 protect the myocardium from further ischemic insult. Alternatively, when the substrate priming (i.e., enhanced FFA extraction) carries over into the second occlusion cycle, it may have deleterious consequences, as indicated by the observation of postischemic dysfunction.
Adenine nucleotides in recurrent ischemia. Repetitive ischemic episodes of short duration do not apparently produce a cumulative effect on adenine nucleotide loss from myocardial tissue. It has been suggested that the largest decline in myocardial ATP occurs after the first occlusion (10 or 15 min duration), with a slower rate of depletion in subsequent episodes.4 34 3 It is not yet known whether this difference in ATP hydrolysis between first and subsequent ischemic episodes occurs in preparations of shorter duration such as that used in our study. We assume that the reduction in myocardial adenine nucleotides should be the same in all groups after the first occlusion period since collateral blood flow and MVO2 in the ischemic zone was similar in all groups in the absence of drug infusions. Despite this, both nicorandil and ISDN were effective in preserving myocardial adenine nucleotides when given before and during the second occlusion period. This suggests that while a single 5 min episode of myocardial ischemia may cause hydrolysis of ATP stores, there may not be a concomitant efflux of nucleosides and bases. In such a case, rephosphorylation to normal ATP levels would still be possible on reperfusion. However, in the absence of pharmacologic intervention between the first and second occlusion periods, a progressive loss in tissue energy metabolites probably occurs. Therefore, the largest loss of myocardial adenine nucleotides may well occur after the second ischemic episode in our preparation of repetitive ischemia, in contrast to the preparation of Reimer et al. 34 It was not ascertained in either the preparation of Reimer et al. or in our preparation whether a reduced rate of ATP depletion in subsequent ischemic cycles is related to the degree of functional impairment during the reperfusion period immediately after a previous ischemic interval. Thus, it could be argued that postischemic hypofunction may result in decreased demand for ATP utilization. However, such a scenario would predict that since nicorandil improves contractile function it should result in a greater utilization of myocardial ATP. However, both nicorandil and ISDN attenuated the loss of myocardial adenine nucleotides, despite different levels of postischemic function. This suggests that the preservation of myocardial adenine nucleotides by these drugs proceeds by mechanisms other that preservation of contractile function.
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Postischemic contractile function after recurrent ischemia. Some controversy also exists as to whether repetitive occlusions produce a progressive decrease in regional contractile function. A number of studies," ' 4 including the present one, suggest that %SS progressively decreases after each succeeding ischemic episode. In contrast, Lange et al.2 reported an initial decrease in' contractile function that was not decreased further after a second or third occlusion. Some of this controversy may be related to the variation in experimental protocol including: the duration of the occlusion period, the duration of reperfusion, and the number of occlusion periods. It is also difficult to compare various studies on contractile function since collateral blood flow and area at risk were not provided in all cases. While the occlusion and reperfusion periods in the study by Lange et al.2 are similar to those of the present study, they did not find a progressive deterioration in myocardial contractile function with repeated ischemic episodes. This may be related to the higher2 and more variable36 blood flow values reported by Lange et al. compared with those observed in the present study during ischemia. Higher collateral blood flow during ischemia would be conducive to better recovery of function during reperfusion. While we did show a progressive deterioration in contractile function during subsequent ischemic episodes in untreated hearts, we were also able to demonstrate that our preparation was still sensitive to therapeutic improvement in wall function, despite an initial decline in %SS.
Implications of the study. Our preparation of repeated, brief coronary artery occlusions was used to test the efficacy of nicorandil and ISDN during myocardial ischemia and reperfusion. Our observations may have potential clinical applications for drug testing. In this regard, the choice of cycle for drug intervention may influence the results obtained. The preparation chosen for these studies appears to be ideal since drug intervention occurred at the point of the substrate priming effect. Therefore, interventions at this point may be useful in determining whether a drug will have a beneficial effect on postischemic myocardial dysfunction.
Finally, the low doses of nitrates chosen for this study were well within the range of those that would be used clinically. The results of the study indicate that nicorandil significantly improves postischemic contractile dysfunction independent of hemodynamic changes. The metabolic data suggest that nicorandil may prove to be a more desirable clinical agent than ISDN in the treatment of angina pectoris.
